文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

爱泼斯坦-巴尔病毒驱动的原发性肺淋巴上皮癌的分子发病机制

Epstein-Barr virus-driven molecular pathogenesis of primary pulmonary lymphoepithelial carcinoma.

作者信息

Xie Mingyuan, Yao Dong, Lei Liping, Tang Chengjiang, Mo Biwen

机构信息

Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.

出版信息

Front Oncol. 2025 Aug 13;15:1630415. doi: 10.3389/fonc.2025.1630415. eCollection 2025.

DOI:10.3389/fonc.2025.1630415
PMID:40881855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12380799/
Abstract

Primary Pulmonary Lymphoepithelial Carcinoma (PLEC) is a rare subtype of non-small cell lung cancer (NSCLC) that exhibits a strong association with Epstein-Barr virus (EBV) infection and shows distinctive geographic and ethnic predilections. Over the past decades, significant efforts have been made to elucidate the pathogenic mechanisms of PLEC, and progress in diagnosis, treatment, and disease monitoring has been achieved. This review focuses on EBV-driven oncogenic mechanisms in PLEC and explores the relationship between EBV infection, tumor progression, and clinical prognosis. We further summarize the molecular pathology, tumor immune microenvironment, and clinicopathological characteristics of PLEC. These insights may offer a theoretical foundation for EBV-targeted and immunotherapeutic strategies in PLEC.

摘要

原发性肺淋巴上皮癌（PLEC）是非小细胞肺癌（NSCLC）的一种罕见亚型，与爱泼斯坦-巴尔病毒（EBV）感染密切相关，具有独特的地理和种族倾向。在过去几十年中，人们为阐明PLEC的致病机制做出了巨大努力，并在诊断、治疗和疾病监测方面取得了进展。本综述聚焦于EBV驱动的PLEC致癌机制，探讨EBV感染、肿瘤进展和临床预后之间的关系。我们还总结了PLEC的分子病理学、肿瘤免疫微环境和临床病理特征。这些见解可能为PLEC的EBV靶向治疗和免疫治疗策略提供理论基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/b90b1b37de59/fonc-15-1630415-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/c4e9c4531799/fonc-15-1630415-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/dd0fb09db71e/fonc-15-1630415-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/49e3b99553e4/fonc-15-1630415-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/b90b1b37de59/fonc-15-1630415-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/c4e9c4531799/fonc-15-1630415-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/dd0fb09db71e/fonc-15-1630415-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/49e3b99553e4/fonc-15-1630415-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/172c/12380799/b90b1b37de59/fonc-15-1630415-g004.jpg

相似文献

[1]
Epstein-Barr virus-driven molecular pathogenesis of primary pulmonary lymphoepithelial carcinoma.

Front Oncol. 2025-8-13

[2]
Appraising the life-course impact of Epstein-Barr virus exposure and its genetic signature on periodontitis.

J Periodontol. 2024-11-4

[3]
X-Linked Lymphoproliferative Disease

1993

[4]
Histone variant H2A.Z cooperates with EBNA1 to maintain Epstein-Barr virus latent epigenome.

mBio. 2025-7-14

[5]
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.

Cancer Treat Rev. 2024-6

[6]
Epstein-Barr virus (EBV) serology and its impact on oral human papillomavirus (HPV) infection outcomes in children during early childhood.

Microbiol Spectr. 2025-9-2

[7]
Epstein-Barr virus (EBV) infection of endothelial cells via endocytosis is associated with a poor prognosis in nasopharyngeal carcinoma.

Microbiol Spectr. 2025-8-5

[8]
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.

Front Immunol. 2025-7-24

[9]
Epstein-Barr virus type 2 infection is associated with higher viral loads in pediatric tonsils from western Kenya.

Microbiol Spectr. 2025-8-5

[10]
Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study.

Clin Exp Rheumatol. 2025-7

本文引用的文献

[1]
Adoptive Cell Immunotherapy in Relapse/Refractory Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorders.

Antibodies (Basel). 2025-6-12

[2]
Single-cell analysis reveals transcriptomic features and therapeutic targets in primary pulmonary lymphoepithelioma-like carcinoma.

Commun Biol. 2025-3-8

[3]
Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma.

Lung Cancer. 2025-1

[4]
Lymphoepithelial Carcinoma of the Lung: A Case Report and Review of the Literature.

Cureus. 2024-9-27

[5]
Exploratory evidence maps for the WHO Classification of Tumours 5th edition for lung and thymus tumors.

Virchows Arch. 2024-11

[6]
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion.

J Immunother Cancer. 2024-6-17

[7]
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinoma.

Clin Transl Immunology. 2024-6-3

[8]
Combination of chemotherapy and immunotherapy may overcome the resistance to immunotherapy alone in pulmonary lymphoepithelial carcinoma.

Kaohsiung J Med Sci. 2024-6

[9]
Epigenetic Mechanisms in Latent Epstein-Barr Virus Infection and Associated Cancers.

Cancers (Basel). 2024-2-29

[10]
Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex.

Nat Commun. 2024-1-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索